Would you prescribe metformin to improve prostate cancer patient outcomes?
Studies looking at the effect of the diabetes drug metformin on prostate cancer (PCa) development and outcomes have yielded conflicting results. For example, two studies published recently reached different conclusions.
A study by a Canadian research team found that increased cumulative metformin use after a PCa diagnosis was associated with a significantly decreased risk of cancer-specific and all-cause mortality, whereas a team at Mayo Clinic found no significant effect of metformin use on the risk of biochemical recurrence, systemic progression, and all-cause mortality and no significant effect on pathologic findings.
Renal & Urology News would like to know if urologists believe the evidence supports the use of metformin in PCa patients, so please answer the following poll question.